ASCO 2015 | TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey Oxnard, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer.